Vimarsana
Biggest News Aggregation in the World

Page 19 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of "Moderate Buy" from Brokerages - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Receives Average Recommendation of "Moderate Buy" from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among […]

DelveInsight Business Research, LLP: PD1 and PDL1 Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Incyte Corporation, Bristol-Myers Squibb, Novartis, Bayer, Beigene, Merck, AbbVie, and Others Expected to Propel Market - Vimarsana News

DelveInsight Business Research, LLP: PD1 and PDL1 Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Incyte Corporation, Bristol-Myers Squibb, Novartis, Bayer, Beigene, Merck, AbbVie, and Others Expected to Propel Market

The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In

BeiGene, Ltd. (NASDAQ:BGNE) Shares Bought by Van ECK Associates Corp - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Shares Bought by Van ECK Associates Corp

Van ECK Associates Corp grew its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) by 68.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,951 shares of the company’s stock after acquiring an additional 37,698 shares during the period. Van […]

Source: wkrb13.com
BeiGene (NASDAQ:BGNE) Issues Earnings Results - Vimarsana News

BeiGene (NASDAQ:BGNE) Issues Earnings Results

BeiGene (NASDAQ:BGNE – Get Rating) posted its earnings results on Thursday. The company reported ($3.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.66) by $0.32, Briefing.com reports. The firm had revenue of $447.80 million during the quarter, compared to analysts’ expectations of $449.44 million. BeiGene had a negative net margin […]

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China - Vimarsana News

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),